Salvatore Alesci
Corporate Officer/Principal bei TAKEDA PHARMACEUTICAL COMPANY LIMITED
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Christophe Weber | M | 57 | 10 Jahre | |
| Krishnan Nandabalan | M | 61 |
Invea Therapeutics, Inc.
 Invea Therapeutics, Inc. BiotechnologyHealth Technology Invea Therapeutics, Inc. operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases. Its products include INVA8001 and INVA8003. The company was founded on October 20, 2021. The company is headquartered in Guilford, CT. | 3 Jahre |
| Masami Iijima | M | 73 | 3 Jahre | |
| Constantine Saroukos | M | 53 | 9 Jahre | |
| Andrew Plump | M | 58 | 9 Jahre | |
| Yoshiaki Fujimori | M | 71 | 8 Jahre | |
| Patricia Spera | M | - |
Invea Therapeutics, Inc.
Invea Therapeutics, Inc. BiotechnologyHealth Technology Invea Therapeutics, Inc. operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases. Its products include INVA8001 and INVA8003. The company was founded on October 20, 2021. The company is headquartered in Guilford, CT. | 3 Jahre |
| Miki Tsusaka | F | 61 | 1 Jahre | |
| Jason Fenton | M | 48 |
Invea Therapeutics, Inc.
Invea Therapeutics, Inc. BiotechnologyHealth Technology Invea Therapeutics, Inc. operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases. Its products include INVA8001 and INVA8003. The company was founded on October 20, 2021. The company is headquartered in Guilford, CT. | 2 Jahre |
| Kimberly Reed | F | 53 | 2 Jahre | |
| Takashi Okubo | M | - | - | |
| Jean-Luc Butel | M | 67 | 8 Jahre | |
| Norimasa Takeda | M | - | - | |
| Jonathan Zalevsky | M | 49 |
Invea Therapeutics, Inc.
Invea Therapeutics, Inc. BiotechnologyHealth Technology Invea Therapeutics, Inc. operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases. Its products include INVA8001 and INVA8003. The company was founded on October 20, 2021. The company is headquartered in Guilford, CT. | 3 Jahre |
| Michel Orsinger | M | 66 | 8 Jahre | |
| Steven Gillis | M | 71 | 5 Jahre | |
| Ian Clark | M | 62 | 5 Jahre | |
| Koji Hatsukawa | M | 72 | 8 Jahre | |
| Emiko Higashi | F | 64 | 8 Jahre | |
| Demetrios Kydonieus | M | 54 |
Invea Therapeutics, Inc.
Invea Therapeutics, Inc. BiotechnologyHealth Technology Invea Therapeutics, Inc. operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases. Its products include INVA8001 and INVA8003. The company was founded on October 20, 2021. The company is headquartered in Guilford, CT. | 3 Jahre |
| Haruhiko Hirate | M | - | - | |
| Kerrie L. Brady | F | 62 |
Invea Therapeutics, Inc.
Invea Therapeutics, Inc. BiotechnologyHealth Technology Invea Therapeutics, Inc. operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases. Its products include INVA8001 and INVA8003. The company was founded on October 20, 2021. The company is headquartered in Guilford, CT. | 3 Jahre |
| John Maraganore | M | 60 | 2 Jahre | |
| Jun Ueki | M | - | 5 Jahre | |
| Michael Mendelsohn | M | 69 | 9 Jahre | |
| Gabriele Ricci | M | 45 | 2 Jahre | |
| Ramy Riad | M | - | 5 Jahre | |
| Lauren Duprey | F | 40 | - | |
| Shunichiro Okada | M | 66 |
Invea Therapeutics, Inc.
Invea Therapeutics, Inc. BiotechnologyHealth Technology Invea Therapeutics, Inc. operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases. Its products include INVA8001 and INVA8003. The company was founded on October 20, 2021. The company is headquartered in Guilford, CT. | 2 Jahre |
| Aman Kant | M | 40 |
Invea Therapeutics, Inc.
Invea Therapeutics, Inc. BiotechnologyHealth Technology Invea Therapeutics, Inc. operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases. Its products include INVA8001 and INVA8003. The company was founded on October 20, 2021. The company is headquartered in Guilford, CT. | 3 Jahre |
| Sheryl Bauer | F | - |
Invea Therapeutics, Inc.
Invea Therapeutics, Inc. BiotechnologyHealth Technology Invea Therapeutics, Inc. operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases. Its products include INVA8001 and INVA8003. The company was founded on October 20, 2021. The company is headquartered in Guilford, CT. | 2 Jahre |
| Elizabeth Borgeson | F | - | - | |
| Julie So-Young Kim | F | - | - | |
| Christopher O'Reilly | M | - | 13 Jahre | |
| Marcello Agosti | M | 53 | 5 Jahre | |
| Ricardo Marek | M | - | - | |
| Chris Slavinsky | M | 52 | - | |
| Satoru Takemoto | M | - | - | |
| Michael Aiello | M | 44 |
Invea Therapeutics, Inc.
Invea Therapeutics, Inc. BiotechnologyHealth Technology Invea Therapeutics, Inc. operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases. Its products include INVA8001 and INVA8003. The company was founded on October 20, 2021. The company is headquartered in Guilford, CT. | 3 Jahre |
| Teresa Bitetti | F | - | - | |
| Rupa Cornell | M | - | - | |
| Yoshihiro Nakagawa | M | 45 | - | |
| Mwana Lugogo | M | 54 | 12 Jahre | |
| Giles Platford | M | - | 7 Jahre | |
| Anita Ganjoo | M | - |
Invea Therapeutics, Inc.
Invea Therapeutics, Inc. BiotechnologyHealth Technology Invea Therapeutics, Inc. operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases. Its products include INVA8001 and INVA8003. The company was founded on October 20, 2021. The company is headquartered in Guilford, CT. | 3 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Sandeep Laumas | M | 56 |
Invea Therapeutics, Inc.
Invea Therapeutics, Inc. BiotechnologyHealth Technology Invea Therapeutics, Inc. operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases. Its products include INVA8001 and INVA8003. The company was founded on October 20, 2021. The company is headquartered in Guilford, CT. | - |
| Vimal Mehta | M | 63 |
Invea Therapeutics, Inc.
Invea Therapeutics, Inc. BiotechnologyHealth Technology Invea Therapeutics, Inc. operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases. Its products include INVA8001 and INVA8003. The company was founded on October 20, 2021. The company is headquartered in Guilford, CT. | - |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Japan | 34 | 72,34% |
| Vereinigte Staaten | 13 | 27,66% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Salvatore Alesci
- Persönliches Netzwerk
